Okadaic acid induced neurotoxicity: An emerging tool to study Alzheimer's disease pathology

NeuroToxicology

Volumn 37, Issue , 2013, Pages 163-172

  Kamat, Pradip K ^a   Rai, Shivika ^b   Nath, Chandishwar ^b  

^a University of Louisville School of Medicine   (United States)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Alzheimer's disease; Neurotoxicity; Okadaic acid

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; NERVE DEGENERATION; NEUROTOXICITY SYNDROMES; OKADAIC ACID; RATS;

RATTUS;

EID: 84878863522     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.05.002     Document Type: Review

References (130)

1. Abraha A., Ghoshal N., Gamblin T.C., Cryns V., Berry R.W., Kuret J., et al. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 2000, 113(Pt 21):3737-3745.
2. Ahn K.H., Kim Y.S., Kim S.Y., Huh Y., Park C., Jeong J.W. Okadaic acid protects human neuroblastoma SH-SY5Y cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis. Neurosci Lett 2009, 449(2):93-97.
3. Arias C., Sharma N., Davies P., Shafit-Zagardo B. Okadaic acid induces early changes in microtubule-associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. J Neurochem 1993, 61(2):673-682.
4. Arias C., Becerra-Garcia F., Arrieta I., Tapia R. The protein phosphatase inhibitor okadaic acid induces heat shock protein expression and neurodegeneration in rat hippocampus in vivo. Exp Neurol 1998, 153(2):242-254.
5. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007, 8(9):663-672.
6. Ballatore C., Brunden K.R., Huryn D.M., Trojanowski J.Q., Lee V.M., Smith A.B. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. J Med Chem 2012, 55(21):8979-8996.
7. Bennett P.C., Zhao W., Ng K.T. Concentration-dependent effects of protein phosphatase (PP) inhibitors implicate PP1 and PP2A in different stages of memory formation. Neurobiol Learn Mem 2001, 75(1):91-110.
8. Bennett P.C., Moutsoulas P., Lawen A., Perini E., Ng K.T. Novel effects on memory observed following unilateral intracranial administration of okadaic acid, cyclosporin A, FK506 and [MeVal4]CyA. Brain Res 2003, 988(1-2):56-68.
9. Bialojan C., Takai A. Inhibitory effect of a marine- sponge toxin, okadaic acid, on protein phosphatases. Biochem J 1988, 256:283-290.
10. Binder L.I., Guillozet-Bongaarts A.L., Garcia-Sierra F., Berry R.W. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 2005, 1739(2-3):216-223.
11. Blass J.P., Baker A.C., Ko L., Black R.S. Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol 1990, 47(8):864-869.
12. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361(6407):31-39.
13. Boe R., Gjertsen B.T., Vintermyr O.K., Houge G., Lanotte M., Doskeland S.O. The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Exp Cell Res 1991, 195(1):237-246.
14. Butterfield D.A., Pocernich C.B. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 2003, 17:641-652.
15. Cagnoli C.M., Kharlamov E., Atabay C., Uz T., Manev H. Apoptosis induced in neuronal cultures by either the phosphatase inhibitor okadaic acid or the kinase inhibitor staurosporine is attenuated by isoquinolinesulfonamides H-7, H-8, and H-9. J Mol Neurosci 1996, 7(1):65-76.
16. Capetillo-Zarate E., Gracia L., Tampellini D., Gouras G.K. Intraneuronal Aβ accumulation, amyloid plaques, and synapse pathology in Alzheimer's disease. Neurodegener Dis 2012, 10(1-4):56-59.
17. Cardoso S.M., Proenca M.T., Santos S., Santana I., Oliveira C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 2004, 25(1):105-110.
18. Cardoso S.M., Santana I., Swerdlow R.H., Oliveira C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 2004, 89(6):1417-1426.
19. Chopra K., Misra S., Kuhad A. Neurobiological aspects of Alzheimer's disease. Expert Opin Ther Targets 2011, 15(5):535-555.
20. Clarke N.A., Webster M., Francis P.T., Procter A.W., Hodgkiss A.D., Bowen D.M. β-Amyloid precursor protein-like immunoreactivity can be altered in humans by drugs affecting neurotransmitter function. Neurodegeneration 1993, 2:243-248.
21. Cohen P. The structure and regulation of protein phosphatases. Adv Second Messenger Phosphoprotein Res 1990, 24:230-235.
22. Collingridge G.L., Isaac J.T., Wang Y.T. Receptor trafficking and synaptic plasticity. Nat Rev Neurosci 2004, 5(12):952-962.
23. Costa A.P., Tramontina A.C., Biasibetti R., Batassini C., Lopes M.W., Wartchow K.M., Bernardi C., Tortorelli L.S., Leal R.B., Goncalves C.A. Neuroglial alterations in rats submitted to the okadaic acid-induced model of dementia. Behav Brain Res 2012, 226(2):420-427.
24. Cui H., Kong Y., Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct 2012, 646354.
25. Dalley J.W., Theobald D.E., Berry D., Milstein J.A., Laane K., Everitt B.J., et al. Cognitive sequelae of intravenous amphetamine self-administration in rats: evidence for selective effects on attentional performance. Neuropsychopharmacology 2005, 30(3):525-537.
26. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990, 27(5):457-464.
27. Del Barrio L., Martin-de-Saavedra M.D., Romero A., Parada E., Egea J., Avila J., et al. Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by alpha7 and beta2* nicotinic stimulation. Toxicol Sci 2011, 123(1):193-205.
28. Dickey C.A., Kamal A., Lundgren K., Klosak N., Bailey R.M., Dunmore J., et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007, 117(3):648-658.
29. Dolan P.J., Johnson G.V. The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel 2010, 13(5):595-603.
30. Douglas P., Moorhead G.B., Ye R., Lees-Miller S.P. Protein phosphatases regulate DNA-dependent protein kinase activity. J Biol Chem 2001, 276(22):18992-18998.
31. Eikelenboom P., Rozemuller A.J., Hoozemans J.J., Veerhuis R., van Gool W.A. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis Assoc Disord 2000, 14(Suppl. 1):S54-S61.
32. Eikelenboom P., van Exel E., Hoozemans J.J., Veerhuis R., Rozemuller A.J., van Gool W.A. Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis 2010, 7(1-3):38-41.
33. Emmerling M.R., Spiegel K., Watson M.D. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. Immunopharmacology 1997, 38(1-2):101-109.
34. Evans D.B., Rank K.B., Bhattacharya K., Thomsen D.R., Gurney M.E., Sharma S.K. Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly. J Biol Chem 2000, 275(32):24977-24983.
35. Fernandez M.T., Zitko V., Gascon S., Novelli A. The marine toxin okadaic acid is a potent neurotoxin for cultured cerebellar neurons. Life Sci 1991, 49(19):PL157-PL162.
36. Fernandez J.J., Candenas M.L., Souto M.L., Trujillo M.M., Norte M. Okadaic acid, useful tool for studying cellular processes. Curr Med Chem 2002, 9(2):229-262.
37. Fernandez-Sanchez M.T., Garcia-Rodriguez A., Diaz-Trelles R., Novelli A. Inhibition of protein phosphatases induces IGF-1-blocked neurotrophin-insensitive neuronal apoptosis. FEBS Lett 1996, 398(1):106-112.
38. Francis P.T. Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease. Neurodegeneration 1996, 5(4):461-465.
39. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999, 66(2):137-147.
40. Garcia C., Gonzalez V., Cornejo C., Palma-Fleming H., Lagos N. First evidence of dinophysistoxin-1 ester and carcinogenic polycyclic aromatic hydrocarbons in smoked bivalves collected in the Patagonia fjords. Toxicon 2004, 43:121-131.
41. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener 2009, 4:13.
42. Gong C.X., Singh T.J., Grundke-Iqbal I., Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 1993, 61(3):921-927.
43. Gong C.X., Lidsky T., Wegiel J., Zuck L., Grundke-Iqbal I., Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain, implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 2000, 275(8):5535-5544.
44. Gong C.X., Wang J.Z., Iqbal K., Grundke-Iqbal I. Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neurosci Lett 2003, 340(2):107-110.
45. Hampel H., Bürger K., Teipel S.J., Bokde A.L., Zetterberg H., Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008, 4(1):38-48.
46. He J., Yamada K., Zou L.B., Nabeshima T. Spatial memory deficit and neurodegeneration induced by the direct injection of okadaic acid into the hippocampus in rats. J Neural Transm 2001, 108(12):1435-1443.
47. He J., Yang Y., Xu H., Zhang X., Li X.M. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology 2005, 30(8):1511-1520.
48. Hirai T., Nohara R., Ogoh S., Chen L.G., Kataoka K., Li X.H., et al. Serial evaluation of fatty acid metabolism in rats with myocardial infarction by pinhole SPECT. J Nucl Cardiol 2001, 8(4):472-481.
49. Hoozemans J.J., Veerhuis R., Rozemuller A.J., Eikelenboom P. The pathological cascade of Alzheimer's disease: the role of inflammation and its therapeutic implications. Drugs Today (Barc) 2002, 38(6):429-443.
50. Huganir R.L., Greengard P. Regulation of neurotransmitter receptor desensitization by protein phosphorylation. Neuron 1990, 5(5):555-567.
51. Kamat P.K., Tota S., Saxena G., Shukla R., Nath C. Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res 2010, 1309:66-74.
52. Kamat P.K., Tota S., Shukla R., Ali S., Najmi A.K., Nath C. Mitochondrial dysfunction: a crucial event in okadaic acid (ICV) induced memory impairment and apoptotic cell death in rat brain. Pharmacol Biochem Behav 2011, 100(2):311-319.
53. Kamat P.K., Tota S., Rai S., Swarnkar S., Shukla R., Nath C. A study on neuroinflammatory marker in brain areas of okadaic acid (ICV) induced memory impaired rats. Life Sci 2012, 90(19-20):713-720.
54. Kamat P.K., Tota S., Rai S., Shukla R., Ali S., Najmi A.K., et al. Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats. Eur J Pharmacol 2012, 690(1-3):90-98.
55. Kamat P.K., Rai S., Swarnkar S., Shukla R., Ali S., Najmi A.K., Nath C. Okadaic acid-induced tau phosphorylation in rat brain: role of NMDA receptor. Neuroscience 2013, in press. 10.1016/j.neuroscience.2013.01.075.
56. Kar S., Issa A.M., Seto D., Auld D.S., Collier B., Quirion R. Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem 1998, 70(5):2179-2187.
57. Kar S., Slowikowski S.P., Westaway D., Mount H.T. Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 2004, 29(6):427-441.
58. Kins S., Kurosinski P., Nitsch R.M., Gotz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 2003, 163(3):833-843.
59. Koss D.J., Hindley K.P., Riedel G., Platt B. Modulation of hippocampal calcium signalling and plasticity by serine/threonine protein phosphatases. J Neurochem 2007, 102(4):1009-1023.
60. Kunze A., Meissner R., Brando S., Renaud P. Co-pathological connected primary neurons in a microfluidic device for Alzheimer studies. Biotechnol Bioeng 2011, 108(9):2241-2245.
61. Li L., Sengupta A., Haque N., Grundke-Iqbal I., Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004, 566(1-3):261-269.
62. Li X., An W.L., Alafuzoff I., Soininen H., Winblad B., Pei J.J. Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport 2004, 15(14):2237-2240.
63. Li X., Lu F., Wang J.Z., Gong C.X. Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci 2006, 23(8):2078-2086.
64. Lim Y.W., Yoon S.Y., Choi J.E., Kim S.M., Lee H.S., Choe H., et al. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem Biophys Res Commun 2010, 395(2):207-212.
65. Lin H., Vicini S., Hsu F.C., Doshi S., Takano H., Coulter D.A., et al. Axonal alpha7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons. Proc Natl Acad Sci U S A 2012, 107(38):16661-16666.
66. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
67. Liu S.J., Wang J.Z. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002, 23(2):183-187.
68. Liu W., Akhand A.A., Takeda K., Kawamoto Y., Itoigawa M., Kato M., et al. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ 2003, 10(7):772-781.
69. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994, 4(12):1077-1086.
70. Lu Y., Rosenberg P.A. NMDA receptor-mediated extracellular adenosine accumulation is blocked by phosphatase 1/2A inhibitors. Brain Res 2007, 1155:116-124.
71. Maidana M., Carlis V., Galhardi F.G., Yunes J.S., Geracitano L.A., Monserrat J.M., et al. Effects of microcystins over short- and long-term memory and oxidative stress generation in hippocampus of rats. Chem Biol Interact 2006, 159(3):223-234.
72. Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 2011, 58(4):458-471.
73. Mather M., Rottenberg H. Aging enhances the activation of the permeability transition pore in mitochondria. Biochem Biophys Res Commun 2000, 273(2):603-608.
74. Matias W.G., Creppy E.E. Evidence for enterohepatic circulation of okadaic acid in mice. Toxic Subst Mech 1996, 15:405-414.
75. Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O'Connor M., Trojanowski J.Q., et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 1994, 13(4):989-1002.
76. Moreira P.I., Zhu X., Wang X., Lee H.G., Nunomura A., Petersen R.B., et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010, 1802(1):212-220.
77. Murakami T., Kobayashi T., Terasawa T., Ohnishi M., Kato S., Sasahara Y., et al. Characterization of multiple molecular forms of Mg(2+)-dependent protein phosphatase from Saccharomyces cerevisiae. J Biochem 1994, 115(4):762-766.
78. Natalia C.B., Clara T., Fred V.L. Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis 2012, 10.1155/2012/251426.
79. Nicholls D.G., Johnson-Cadwell L., Vesce S., Jekabsons M., Yadava N. Bioenergetics of mitochondria in cultured neurons and their role in glutamate excitotoxicity. J Neurosci Res 2007, 85(15):3206-3212.
80. Nishimura T., Takeda M., Nakamura Y., Yosbida Y., Arai H., Sasaki H., et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find Exp Clin Pharmacol 1998, 20(3):227-235.
81. Nitsch R.M. From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 1996, 5(4):477-482.
82. Nunomura A., Tamaoki T., Tanaka K., Motohashi N., Nakamura M., Hayashi T., et al. Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 2010, 37(3):731-737.
83. Palmer A.M., Procter A.W., Stratmann G.C., Bowen D.M. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci Lett 1986, 66(2):199-204.
84. Paudel H.K. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. J Biol Chem 1997, 272(3):1777-1785.
85. Pera M., Alcolea D., Sanchez-Valle R., Guardia-Laguarta C., Colom-Cadena M., Badiola N., et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol 2013, 125(2):201-213.
86. Perez-Otano I., Ehlers M.D. Learning from NMDA receptor trafficking: clues to the development and maturation of glutamatergic synapses. Neurosignals 2004, 13(4):175-189.
87. Poppek D., Keck S., Ermak G., Jung T., Stolzing A., Ullrich O., et al. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem J 2006, 400(3):511-520.
88. Qian W., Shi J., Yin X., Iqbal K., Grundke-Iqbal I., Gong C.X., et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 2010, 19(4):1221-1229.
89. Radebaugh T.S., Buckholtz N., Khachaturian Z. Behavioral approaches to the treatment of Alzheimer's disease: research strategies. Int Psychogeriatr 1996, 8(Suppl. 1):7-12.
90. Rahman A., Akterin S., Flores-Morales A., Crisby M., Kivipelto M., Schultzberg M., et al. High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 2005, 579(28):6411-6416.
91. Rai S., Kamat P.K., Nath C., Shukla R. A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J Neuroimmunol 2012, pii: S0165-5728(12)00252-4.
92. Reynolds C.H., Garwood C.J., Wray S., Price C., Kellie S., Perera T., et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 2008, 283(26):18177-18186.
93. Sadot E., Gurwitz D., Barg J., Behar L., Ginzburg I., Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996, 66(2):877-880.
94. Sas K., Robotka H., Toldi J., Vecsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007, 257(1-2):221-239.
95. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., et al. Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 2008, 5(2):207-224.
96. Shin D.S., Wilkie M.P., Pamenter M.E., Buck L.T. Calcium and protein phosphatase 1/2A attenuate N-methyl-D-aspartate receptor activity in the anoxic turtle cortex. Comp Biochem Physiol A Mol Integr Physiol 2005, 142(September (1)):50-57.
97. Sueoka E., Sueoka N., Okabe S., Kozu T., Ohta T., Suganuma M., et al. Expression of the tumor necrosis factor alpha gene and early response genes by nodularin, a liver tumor promoter in primary cultured rat hepatocytes. Cancer Res Clin Oncol 1997, 123:413-419.
98. Suuronen T., Kolehmainen P., Salminen A. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochem Pharmacol 2000, 59(12):1589-1595.
99. Takai A., Bialojan C., Troschka M., Ruegg J.C. Smooth muscle phosphatase inhibition and force enhancement by block sponge toxin. FEBS Lett 1987, 217:81-84.
100. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2006, 9(3 Suppl.):309-317.
101. Tanaka S., Fakher M., Barbour S.E., Schenkein H.A., Tew J.G. Influence of proinflammatory cytokines on Actinobacillus actinomycetemcomitans specific IgG responses. J Periodontal Res 2006, 41(1):1-9.
102. Tessier S., Godreau D., Vranckx R., Lang-Lazdunski L., Mercadier J.J., Hatem S.N. Cumulative inactivation of the outward potassium current: a likely mechanism underlying electrical memory in human atrial myocytes. J Mol Cell Cardiol 2001, 33(4):755-767.
103. Thiels E., Kanterewicz B.I., Knapp L.T., Barrionuevo G., Klann E. Protein phosphatase-mediated regulation of protein kinase C during long-term depression in the adult hippocampus in vivo. J Neurosci 2000, 20(19):7199-7207.
104. Tian Q., Lin Z.Q., Wang X.C., Chen J., Wang Q., Gong C.X., et al. Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience 2004, 126(2):277-284.
105. Torrent L., Ferrer I. PP2A and Alzheimer disease. Curr Alzheimer Res 2012, 9(2):248-256.
106. Túnez I., Collado J.A., Medina F.J., Muñoz M.C., Gordillo R., Sampedro C., Moyano M.J., Feijóo M., Muntané J., Montilla P. Protective effect of carvedilol on oxidative stress induced by okadaic acid in N1E-115 cells. Pharmacol Res 2006, 54(3):241-246.
107. Tyagi E., Agrawal R., Nath C., Shukla R. Influence of LPS-induced neuroinflammation on acetylcholinesterase activity in rat brain. J Neuroimmunol 2008, 205(1-2):51-56.
108. Valdiglesias V., Laffon B., Pasaro E., Cemeli E., Anderson D., Mendez J. Induction of oxidative DNA damage by the marine toxin okadaic acid depends on human cell type. Toxicon 2011, 57(6):882-888.
109. van de Nes J.A., Konermann S., Nafe R., Swaab D.F. Beta-protein/A4 deposits are not associated with hyperphosphorylated tau in somatostatin neurons in the hypothalamus of Alzheimer's disease patients. Acta Neuropathol 2006, 111(2):126-138.
110. Wagner U., Utton M., Gallo J.M., Miller C.C. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996, 109(Pt 6):1537-1543.
111. Wang J., Tung Y.C., Wang Y., Li X.T., Iqbal K., Grundke-Iqbal I. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 2001, 507(1):81-87.
112. Wang D.L., Ling Z.Q., Cao F.Y., Zhu L.Q., Wang J.Z. Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 2004, 37(1):11-16.
113. Wang Z., Yang L., Zheng H. Role of APP and Abeta in synaptic physiology. Curr Alzheimer Res 2012, 9(2):217-226.
114. Whitehouse P.J., Kellar K.J. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders. J Neural Transm Suppl 1987, 24:175-182.
115. Wilcock G.K., Esiri M.M., Bowen D.M., Smith C.C. Alzheimer's disease, correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982, 57(2-3):407-417.
116. Wu S., Sasaki A., Yoshimoto R., Kawahara Y., Manabe T., Kataoka K., et al. Neural stem cells improve learning and memory in rats with Alzheimer's disease. Pathobiology 2008, 75(3):186-194.
117. Yamaguchi R., Perkins G. Dynamics of mitochondrial structure during apoptosis and the enigma of Opa1. Biochim Biophys Acta 2009, 1787(8):963-972.
118. Yi K.D., Simpkins J.W. Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated neuroprotection. Endocrinology 2008, 149(10):5235-5243.
119. Yi K.D., Chung J., Pang P., Simpkins J.W. Role of protein phosphatases in estrogen-mediated neuroprotection. J Neurosci 2005, 25(31):7191-7198.
120. Yi K.D., Covey D.F., Simpkins J.W. Mechanism of okadaic acid-induced neuronal death and the effect of estrogens. J Neurochem 2009, 108(3):732-740.
121. Yin Y.Y., Liu H., Cong X.B., Liu Z., Wang Q., Wang J.Z., et al. Acetyl-L-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats. J Alzheimers Dis 2010, 19(2):735-746.
122. Yoon S.Y., Choi J.E., Yoon J.H., Huh J.W., Kim D.H. BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol Dis 2006, 22(2):435-444.
123. Zhang Y., Herman B. Apoptosis and successful aging. Mech Ageing Dev 2002, 123(6):563-565.
124. Zhang Z., Simpkins J.W. Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. Brain Res 2010, 1345:176-181.
125. Zhang Z., Simpkins J.W. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res 2010, 1359:233-246.
126. Zhang J., Cheng Y., Zhang J.T. Protective effect of (-) clausenamide against neurotoxicity induced by okadaic acid and beta-amyloid peptide25-3. Yao Xue Xue Bao 2007, 42(9):935-942.
127. Zhao W.Q., Sedman G.L., Gibbs M.E., Ng K.T. Effect of PKC inhibitors and activators on memory. Behav Brain Res 1994, 60(2):151-160.
128. Zheng L., Kågedal K., Dehvari N., Benedikz E., Cowburn R., Marcusson J., et al. Oxidative stress induces macroautophagy of amyloid beta-protein and ensuing apoptosis. Free Radicl Biol Med 2009, 46:422-429.
129. Zhou X.W., Gustafsson J.A., Tanila H., Bjorkdahl C., Liu R., Winblad B., et al. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis 2008, 31(3):386-394.
130. Zimmer E.R., Kalinine E., Haas C.B., Torrez V.R., Souza D.O., Muller A.P., et al. Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats. Curr Alzheimer Res 2012 Dec, 9(10):1182-1190.